Skip to content

Lung squamous cell carcinoma — overview

TL;DR

  • Lung squamous cell carcinoma (LUSC) is a non-small-cell lung cancer (NSCLC) defined by squamous morphology and lineage markers, strongly but not exclusively linked to tobacco exposure and often arising in central bronchi.
  • A current model estimated 616,769 incident LUSC cases worldwide in 2022—461,171 in men and 155,598 in women. Histology-specific mortality is not reliably registered, so this incidence estimate should not be relabelled as deaths.
  • LUSC couples a heavy smoking mutational burden with extensive copy-number and tumour-suppressor alterations. The genome is well mapped but usually lacks a simple clonal kinase addiction; FGFR, PI3K, DDR2, and other target programs have repeatedly failed to produce a broadly effective histology-specific therapy.
  • Histology is a treatment and safety gate: pemetrexed performs poorly in squamous disease and bevacizumab is generally avoided because of pulmonary-haemorrhage risk. Squamous-compatible platinum/taxane regimens remain foundational.
  • Checkpoint blockade changed outcomes. Pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel has direct first-line metastatic LUSC evidence across PD-L1 strata; perioperative chemo-immunotherapy now improves event-free survival and pathological response in resectable NSCLC.
  • Central-airway obstruction, haemoptysis, post-obstructive infection, hypercalcaemia, COPD, cardiovascular disease, and stigma demand as much attention as drug selection.

What LUSC is—and is not

LUSC is an epithelial lung malignancy with keratinization, intercellular bridges, and/or a compatible immunophenotype. On small samples, diffuse nuclear p40 supports squamous differentiation, while TTF-1 supports adenocarcinoma; neither marker alone identifies the organ of origin. Metastatic squamous carcinoma from head and neck, skin, cervix, oesophagus, or another site can mimic a lung primary.

Question Anchor answer Consequence
Is the sample malignant? Morphology plus adequate viable tissue Avoids biomarker testing on necrosis or reactive epithelium
Is it NSCLC or small-cell/neuroendocrine carcinoma? Cell size, architecture, mitoses/necrosis, targeted IHC Changes staging emphasis, regimen, and urgency
Is there squamous differentiation? Keratinization/intercellular bridges or p40-dominant profile Controls chemotherapy and bleeding-risk choices
Is lung the primary site? Clinical/radiological distribution plus site-specific differential p40 cannot distinguish pulmonary from extrapulmonary SCC
Is the biopsy representative? Correlate with resection, multiple sites, and molecular phenotype Mixed adenosquamous disease and transformation can be missed
Is tissue sufficient for PD-L1 and sequencing? Pathologist-led tissue stewardship Prevents serial stains from exhausting the only sample

Modern small-biopsy classification deliberately minimizes NSCLC-not otherwise specified because histology changes therapy ([PMID 21252716](https://pubmed.ncbi.nlm.nih.gov/21252716/){target="_blank" rel="noopener"}). Molecular-testing standards require validated methods, adequate tumour, and clinically useful turnaround ([PMID 29398453](https://pubmed.ncbi.nlm.nih.gov/29398453/){target="_blank" rel="noopener"}).

Burden and causation

A 2022 global model estimated 461,171 male and 155,598 female LUSC cases, representing 29.4% and 17.1% of lung cancers in those groups ([PMID 39914442](https://pubmed.ncbi.nlm.nih.gov/39914442/){target="_blank" rel="noopener"}). The estimate combines GLOBOCAN totals with registry subtype fractions and redistribution of unspecified histology; its apparent precision does not remove model uncertainty.

Exposure or pattern Quantitative anchor Interpretation
Heavy current smoking >30 cigarettes/day vs never: odds ratio (OR) 103.5 in men and 62.7 in women Extreme case-control contrast; demonstrates the steep LUSC dose–response ([PMID 22052329](https://pubmed.ncbi.nlm.nih.gov/22052329/){target="_blank" rel="noopener"})
Residential radon Highest vs lowest exposure: LUSC OR 1.43 (95% CI 1.18–1.74) Association survives subtype analysis but remains vulnerable to smoking/exposure error ([PMID 32102460](https://pubmed.ncbi.nlm.nih.gov/32102460/){target="_blank" rel="noopener"})
Asbestos Ever-exposed men: overall lung-cancer OR 1.24; risk increased across major subtypes Joint smoking–asbestos effects matter; subtype attributable fractions are uncertain ([PMID 28141674](https://pubmed.ncbi.nlm.nih.gov/28141674/){target="_blank" rel="noopener"})
Global sex pattern About three quarters of modeled 2022 LUSC cases occurred in men Reflects historical exposure, geography, and diagnosis, not sex as a causal substitute
Trend Squamous share declined in many high-income registries Tobacco control and classification shifts both contribute ([PMID 25822850](https://pubmed.ncbi.nlm.nih.gov/25822850/){target="_blank" rel="noopener"})

Smoking cessation remains active cancer care. Quitting at or around diagnosis was associated with lower all-cause mortality in NSCLC (summary relative risk 0.77, 95% CI 0.66–0.90), although the evidence is observational ([PMID 34995798](https://pubmed.ncbi.nlm.nih.gov/34995798/){target="_blank" rel="noopener"}). Support should combine behavioural and pharmacological treatment without blame.

Central-airway biology and presentation

Many LUSCs arise through a bronchial field-injury sequence from basal-cell hyperplasia and squamous metaplasia through dysplasia and carcinoma in situ to invasion. Tobacco-damaged epithelium can contain spatially separated molecularly altered clones, helping explain synchronous lesions and second primaries.

Central location creates disproportionate clinical risk:

Mechanism Presentation Pitfall
Endobronchial narrowing Monophonic wheeze, dyspnoea, lobar collapse Mislabelled as COPD/asthma without imaging/bronchoscopy
Post-obstructive infection Fever, sputum, recurrent same-lobe pneumonia Antibiotics without source control
Friable neovascular tumour Haemoptysis Volume underestimates airway threat
Cavitation/necrosis Air–fluid level, infection, fistula, bleeding Radiographic enlargement may be necrosis or infection, not simple progression
Main-bronchus/carina invasion Small radial tumour with advanced T descriptor Diameter alone understages anatomy
Paraneoplastic PTHrP Hypercalcaemia, dehydration, confusion Symptoms attributed to treatment or frailty

Symptomatic central-airway obstruction requires multidisciplinary bronchoscopy, radiation, and systemic planning; the CHEST guideline treats therapeutic bronchoscopy as an adjunct rather than a competing oncology pathway ([PMID 39029785](https://pubmed.ncbi.nlm.nih.gov/39029785/){target="_blank" rel="noopener"}).

Screening and diagnosis are different pathways

Low-dose CT screening reduces lung-cancer mortality in eligible asymptomatic high-risk populations. NLST found a 20% relative lung-cancer-mortality reduction versus chest radiography ([PMID 21714641](https://pubmed.ncbi.nlm.nih.gov/21714641/){target="_blank" rel="noopener"}); NELSON independently demonstrated a mortality reduction using volume CT ([PMID 31995683](https://pubmed.ncbi.nlm.nih.gov/31995683/){target="_blank" rel="noopener"}). Screening does not apply to haemoptysis, progressive cough, focal wheeze, weight loss, or suspicious imaging—those require diagnostic evaluation.

Central and hilar LUSCs can be radiographically occult or difficult to measure. Bronchoscopy is therefore particularly important when CT suggests airway involvement or symptoms remain discordant. Autofluorescence and other optical methods can improve detection of central preinvasive lesions in selected high-risk research/surveillance settings, but they are not population-screening replacements.

Stage is anatomy, not destiny

LUSC uses the same TNM system as other lung carcinomas. The ninth edition retains eighth-edition T categories, subdivides N2 into single-station N2a and multistation N2b, and subdivides M1c by one versus multiple organ systems ([PMID 38447919](https://pubmed.ncbi.nlm.nih.gov/38447919/){target="_blank" rel="noopener"}; [PMID 38320664](https://pubmed.ncbi.nlm.nih.gov/38320664/){target="_blank" rel="noopener"}).

Staging task Minimum standard Why it matters in LUSC
Primary tumour Contrast CT; bronchoscopy when central Main bronchus, carina, collapse, and adjacent-structure invasion change T
Mediastinum PET-CT plus EBUS/EUS or surgical confirmation where management changes Central tumours carry substantial occult nodal risk
Brain Stage/symptom-appropriate MRI or CT Prevents futile thoracic-only curative treatment
Distant lesions Confirm isolated findings before abandoning curative intent Second primary, inflammation, and metastasis can resemble one another
Operability Spirometry, diffusing capacity, predicted postoperative function, exercise/cardiac/frailty assessment Smoking-related competing disease is common
Resectability Prospective thoracic multidisciplinary decision Stage III spans resectable to unequivocally unresectable anatomy

Clinical stage, pathological stage, and post-neoadjuvant stage must not be substituted for each other. A pathological complete response after induction therapy does not erase the baseline stage that determined eligibility.

Genomic landscape: altered is not actionable

TCGA characterized 178 LUSCs and found highly complex genomes with near-ubiquitous TP53 alteration and recurrent changes in CDKN2A/RB1, oxidative-stress, PI3K, squamous-differentiation, and chromatin pathways ([PMID 22960745](https://pubmed.ncbi.nlm.nih.gov/22960745/){target="_blank" rel="noopener"}). Smoking-associated mutational burden can generate neoantigens, but immune escape and metabolic resistance can dominate.

Pathway Representative events Clinical state
Cell cycle TP53, CDKN2A loss, RB1 alterations, CCND1 amplification Common; no routine mutation-specific LUSC therapy
Squamous lineage SOX2/TP63 amplification, NOTCH-pathway disruption Defines state; potential dependency is context-dependent
Oxidative stress NFE2L2, KEAP1, CUL3 Adverse/metabolic and immune-resistance biology; active trial target
PI3K/AKT PIK3CA mutation/amplification, PTEN loss Heterogeneous and often subclonal; matched inhibitors disappointed
FGFR FGFR1 amplification, less often mutation/fusion Amplification prevalence did not translate into broad inhibitor benefit
DDR2 Kinase-domain mutations in a minority Preclinical sensitivity and exceptional responses did not establish a standard
Antigen presentation HLA loss/alteration, clonal heterogeneity Can uncouple high TMB from immune response

FGFR1 amplification was reported in roughly one fifth of early discovery cohorts and created a compelling dependency hypothesis ([PMID 21160078](https://pubmed.ncbi.nlm.nih.gov/21160078/){target="_blank" rel="noopener"}). Its failure illustrates the core LUSC problem: copy-number threshold, expression, clonality, co-drivers, and normal-tissue toxicity all stand between association and addiction.

Lung-MAP was built as a biomarker-driven master protocol to screen and test multiple hypotheses efficiently ([PMID 25680375](https://pubmed.ncbi.nlm.nih.gov/25680375/){target="_blank" rel="noopener"}). It proved platform feasibility and made negative substudies visible; it did not make every biomarker a viable target.

Biomarkers in practice

PD-L1 tumour proportion score (TPS) is the principal routine immune marker in metastatic driver-negative LUSC. Assay context matters: Blueprint found 22C3, 28-8, and SP263 tumour-cell staining broadly comparable, while SP142 stained fewer tumour cells; immune-cell scoring was less concordant ([PMID 27913228](https://pubmed.ncbi.nlm.nih.gov/27913228/){target="_blank" rel="noopener"}). Spatial/temporal heterogeneity and small-biopsy sampling limit certainty.

Biomarker Use now Important “no”
PD-L1 TPS Helps choose immune monotherapy vs combination TPS 0% does not prove no benefit; ≥50% does not guarantee response
Broad DNA/RNA panel Finds rare actionable drivers and trial eligibility Negative plasma does not equal tumour wild type
TMB Biological/research stratifier and selected historical trial context No universal cross-assay cut-off or routine stand-alone choice
KEAP1/NFE2L2 Prognosis and trial stratification Do not withhold standard immunotherapy solely from retrospective association
Postoperative ctDNA Strong recurrence-risk research marker Not yet universal proof to escalate or omit therapy
Serum CYFRA 21-1/SCC antigen Occasional adjunct if elevated at baseline Not a screening, diagnostic, or imaging replacement

ctDNA can anticipate radiographic relapse after curative treatment ([PMID 28899864](https://pubmed.ncbi.nlm.nih.gov/28899864/){target="_blank" rel="noopener"}) and track metastatic dissemination ([PMID 37055640](https://pubmed.ncbi.nlm.nih.gov/37055640/){target="_blank" rel="noopener"}). The missing step is randomized evidence that acting on the result improves survival.

Treatment map

Clinical state Reference strategy LUSC-specific qualification
Operable stage I Lobectomy with systematic nodal evaluation Selected peripheral tumours ≤2 cm may undergo protocol-defined segmentectomy/sublobar resection ([PMID 35461558](https://pubmed.ncbi.nlm.nih.gov/35461558/){target="_blank" rel="noopener"}; [PMID 36780674](https://pubmed.ncbi.nlm.nih.gov/36780674/){target="_blank" rel="noopener"})
Medically inoperable stage I Stereotactic ablative radiotherapy Central/ultracentral anatomy changes fractionation and bleeding/airway risk
Resected stage II–III Cisplatin-based adjuvant chemotherapy LACE: death hazard ratio (HR) 0.89; absolute five-year survival gain 5.4 percentage points ([PMID 18506026](https://pubmed.ncbi.nlm.nih.gov/18506026/){target="_blank" rel="noopener"})
Resectable higher-risk stage II–III Neoadjuvant or perioperative chemo-immunotherapy CheckMate 816 EFS HR 0.63 and pCR 24.0% vs 2.2% ([PMID 35403841](https://pubmed.ncbi.nlm.nih.gov/35403841/){target="_blank" rel="noopener"})
Unresectable stage III Concurrent platinum chemoradiation then durvalumab if no progression PACIFIC five-year OS 42.9% vs 33.4% ([PMID 35108059](https://pubmed.ncbi.nlm.nih.gov/35108059/){target="_blank" rel="noopener"})
Metastatic, any PD-L1 Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel KEYNOTE-407 OS HR 0.64 initially; five-year OS 18.4% vs 9.7% ([PMID 30280635](https://pubmed.ncbi.nlm.nih.gov/30280635/){target="_blank" rel="noopener"}; [PMID 36735893](https://pubmed.ncbi.nlm.nih.gov/36735893/){target="_blank" rel="noopener"})
Metastatic, PD-L1 high Selected PD-1/PD-L1 monotherapy or combination Disease tempo, burden, comorbidity, and early-progression risk shape the choice
Progression after chemo-immunotherapy Trial, docetaxel ± ramucirumab, gemcitabine, selected other therapy Evidence is weaker than first-line; re-biopsy and trial search matter

CheckMate 017 first established a direct squamous survival gain for nivolumab over docetaxel after platinum: median OS 9.2 versus 6.0 months, HR 0.59, with grade 3–4 treatment-related adverse events 7% versus 55% ([PMID 26028407](https://pubmed.ncbi.nlm.nih.gov/26028407/){target="_blank" rel="noopener"}). KEYNOTE-407 then moved immunotherapy to first line ([PMID 30280635](https://pubmed.ncbi.nlm.nih.gov/30280635/){target="_blank" rel="noopener"}).

Histology still polices cytotoxic choices. Pemetrexed benefit is confined to non-squamous NSCLC in treatment-by-histology analyses ([PMID 21119545](https://pubmed.ncbi.nlm.nih.gov/21119545/){target="_blank" rel="noopener"}). Bevacizumab is generally excluded from squamous disease after severe/fatal pulmonary bleeding in early development, particularly concerning in central cavitating tumours.

Immunotherapy: durable minority, resistant majority

Checkpoint inhibition can produce long survival tails, but many patients never respond. PD-L1, TMB, interferon signalling, clonal neoantigens, antigen presentation, T-cell geography, microbiome, steroids, antibiotics, and KEAP1/NFE2L2 biology all contribute.

Perioperative therapy creates additional questions. In CheckMate 816, neoadjuvant nivolumab plus chemotherapy improved EFS and pCR without an adjuvant immune component ([PMID 35403841](https://pubmed.ncbi.nlm.nih.gov/35403841/){target="_blank" rel="noopener"}). KEYNOTE-671, AEGEAN, and CheckMate 77T add postoperative checkpoint therapy, but their designs cannot isolate its marginal value ([PMID 39288781](https://pubmed.ncbi.nlm.nih.gov/39288781/){target="_blank" rel="noopener"}; [PMID 37870974](https://pubmed.ncbi.nlm.nih.gov/37870974/){target="_blank" rel="noopener"}; [PMID 38749033](https://pubmed.ncbi.nlm.nih.gov/38749033/){target="_blank" rel="noopener"}).

Safety and lived experience

Domain LUSC emphasis Non-negotiable response
Haemoptysis Central/cavitating anatomy and anticoagulation Physiological severity over volume; emergency airway/embolization pathway
Obstruction Main bronchus/carina, lobar collapse, infection Same-day interventional-pulmonology/radiation review when threatened
COPD/cardiovascular disease Shared tobacco exposure and competing mortality Quantify operability and treatment risk; do not use age alone
Immune toxicity Pneumonitis can mimic infection/radiation/tumour Hold significant toxicity; urgent exclusion of infection/embolus
Hypercalcaemia PTHrP-producing squamous biology Hydration/antiresorptive emergency pathway and tumour control
Stigma Smoking-related blame and self-blame Person-first language, cessation support, equal access and empathy
Financial toxicity Travel, work loss, caregiver time, molecular/trial access Repeated screening and navigation, not a one-time question

Stigma predicts delayed help-seeking and is linked to poorer communication and depression ([PMID 24769603](https://pubmed.ncbi.nlm.nih.gov/24769603/){target="_blank" rel="noopener"}; [PMID 30779396](https://pubmed.ncbi.nlm.nih.gov/30779396/){target="_blank" rel="noopener"}). Early palliative care alongside oncology improved quality of life and mood, reduced aggressive end-of-life care, and was associated with longer survival in metastatic NSCLC ([PMID 20818875](https://pubmed.ncbi.nlm.nih.gov/20818875/){target="_blank" rel="noopener"}).

What explains the precision-oncology gap?

  1. Alterations are often losses or amplifications, not clean kinase mutations. Restoring a tumour suppressor is harder than inhibiting an activated enzyme.
  2. Copy number is not dependency. A focal amplification may not generate sufficient, uniform protein addiction.
  3. Clonality is variable. Target-negative subclones survive and repopulate.
  4. Pathways compensate. PI3K, MAPK, cell-cycle, and oxidative-stress networks bypass single-node inhibition.
  5. Therapeutic windows are narrow. Squamous lineage targets may be shared with normal epithelium, skin, gut, or marrow.
  6. Comorbidity and central anatomy constrain trials. Bleeding, lung reserve, and performance status reduce eligibility.
  7. Control therapy improved. New targeted agents must outperform effective chemo-immunotherapy, not historical chemotherapy.
  8. Histology-wide labels dilute mechanisms. An all-NSCLC positive result can conceal an unfavourable squamous subgroup.

The last point is concrete: in TROPION-Lung01, datopotamab deruxtecan improved PFS overall, driven by non-squamous disease; squamous median PFS was 2.8 versus 3.9 months with docetaxel (HR 1.41) and OS 7.6 versus 9.4 months (HR 1.32) ([PMID 39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/){target="_blank" rel="noopener"}).

Near-term frontier

  • metabolic therapy for NFE2L2/KEAP1-altered immune-resistant disease;
  • ADCs selected by sufficiently homogeneous tumour-surface antigen;
  • personalized neoantigen vaccines and selected T-cell products;
  • ctDNA-guided perioperative escalation/de-escalation;
  • randomized maintenance-duration reduction;
  • local therapy for oligoprogression while preserving systemic benefit;
  • trials designed for ECOG 2–3, COPD, older, rural, and underrepresented populations;
  • LUSC-specific patient-reported measures for haemoptysis, cough, breathlessness, and airway fear.

Open questions

  1. Which composite biomarker can distinguish inflamed, excluded, and metabolically immune-resistant LUSC better than PD-L1 alone?
  2. Can NFE2L2/KEAP1-directed therapy produce a therapeutic window large enough for randomized benefit?
  3. Is postoperative immunotherapy necessary after neoadjuvant pCR or durable ctDNA clearance?
  4. Which surface target is clonal and tumour-selective enough for a successful LUSC ADC?
  5. What is the optimal post-chemo-immunotherapy sequence, measured with survival, function, and quality of life?
  6. Can screening and diagnostic pathways reduce central-airway emergencies without increasing inequitable overdiagnosis?
  7. Which interventions measurably reduce lung-cancer stigma and diagnostic delay?

References

  1. Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13(4):348-363. PMID 39914442
  2. Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210-9. PMID 22052329
  3. Li C, Wang C, Yu J, Fan Y, Liu D, Zhou W, et al. Residential Radon and Histological Types of Lung Cancer: A Meta-Analysis of Case‒Control Studies. Int J Environ Res Public Health. 2020;17(4). PMID 32102460
  4. Olsson AC, Vermeulen R, Schüz J, Kromhout H, Pesch B, Peters S, et al. Exposure-Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Case-Control Studies. Epidemiology. 2017;28(2):288-299. PMID 28141674
  5. Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One. 2015;10(3):e0121323. PMID 25822850
  6. Caini S, Del Riccio M, Vettori V, Scotti V, Martinoli C, Raimondi S, et al. Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2022;17(5):623-636. PMID 34995798
  7. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85. PMID 21252716
  8. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129-159. PMID 29398453
  9. Mahmood K, Frazer-Green L, Gonzalez AV, Shofer SL, Argento AC, Welsby I, et al. Management of Central Airway Obstruction: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025;167(1):283-295. PMID 39029785
  10. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. PMID 21714641
  11. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-513. PMID 31995683
  12. Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(7):1007-1027. PMID 38447919
  13. Fong KM, Rosenthal A, Giroux DJ, Nishimura KK, Erasmus J, Lievens Y, et al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):786-802. PMID 38320664
  14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. PMID 22960745
  15. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. PMID 21160078
  16. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514-24. PMID 25680375
  17. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12(2):208-222. PMID 27913228
  18. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7(12):1394-1403. PMID 28899864
  19. Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553-562. PMID 37055640
  20. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617. PMID 35461558
  21. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023;388(6):489-498. PMID 36780674
  22. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9. PMID 18506026
  23. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. PMID 35403841
  24. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311. PMID 35108059
  25. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. PMID 26028407
  26. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051. PMID 30280635
  27. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006. PMID 36735893
  28. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):64-70. PMID 21119545
  29. Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240-1252. PMID 39288781
  30. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(18):1672-1684. PMID 37870974
  31. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024;390(19):1756-1769. PMID 38749033
  32. Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025;43(3):260-272. PMID 39250535
  33. Carter-Harris L, Hermann CP, Schreiber J, Weaver MT, Rawl SM. Lung cancer stigma predicts timing of medical help-seeking behavior. Oncol Nurs Forum. 2014;41(3):E203-10. PMID 24769603
  34. Ostroff JS, Riley KE, Shen MJ, Atkinson TM, Williamson TJ, Hamann HA. Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory. Psychooncology. 2019;28(5):1011-1017. PMID 30779396
  35. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-42. PMID 20818875